The OS benefit is encouraging but the PFS miss complicates regulatory and commercial prospects for an oncology indication. Watch for Amarin's next steps on further analyses and potential discussions with regulators; the stock may remain volatile until a clearer path is established.
Price Chart
Executive Summary
Amarin announced Phase 3 EMT2 trial results for VAZKEPA/VASCEPA (icosapent ethyl) in colorectal cancer liver metastases (CRCLM). The trial missed its primary endpoint of progression-free survival (PFS) but met the key secondary endpoint of overall survival (OS), showing a 32% reduction in risk of death at 5 years. The mixed results leave the potential oncology indication uncertain, though the OS benefit warrants further study.
Key Facts
- Phase 3 EMT2 trial of VAZKEPA/VASCEPA in colorectal cancer liver metastases did not meet primary endpoint of PFS (median 13.5 vs 12.9 months, HR 0.89, p=0.329)
- Key secondary endpoint of OS showed statistically significant benefit: 5-year OS 62.0% vs 45.1%, HR 0.68, p=0.030 (32% risk reduction)
- Trial enrolled 418 patients across 13 centers in England and Wales
- Safety profile consistent with known profile; no excess adverse events vs placebo
- Patent protection in Europe through 2039 for VAZKEPA/VASCEPA
Financial Impact
Not quantified; potential new oncology indication could expand addressable market significantly, but PFS miss limits likelihood of rapid regulatory path
Risk Factors
- Primary endpoint PFS was not met, which may hinder regulatory approval for an oncology indication
- OS benefit without PFS benefit is unusual and may face skepticism from regulators and clinicians
- Amarin has a small market cap ($245M) and limited pipeline beyond cardiovascular; reliance on VASCEPA/VAZKEPA for growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3387729 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 25, 2026 1d ago | Press Release | $11.41 | awaiting T+60 | — | $12.09 (+5.97%) |
Aug 28, 2026 8w ago | Press Release | $13.97 | awaiting T+60 | — | $12.09 (−13.46%) |
Jun 4, 2026 20w ago | Court Ruling | $13.80 $13.97 | ▼ −1.23% | ▲ +0.65% | $12.09 (+12.39%) |
Apr 29, 2026 25w ago | 8-K | $14.29 $13.55 | ▼ −5.18% | ▼ −9.29% | $12.09 (−15.40%) |
Mar 16, 2026 32w ago | Press Release | $15.42 $14.20 | ▼ −7.91% | ▼ −18.40% | $12.09 (−21.60%) |
Feb 25, 2026 34w ago | 8-K | $14.05 $14.27 | ▼ −1.57% | ▲ +5.38% | $12.09 (+13.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers